ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
US Tech 100
19,884.80
0.46%
Dow Jones
40,211.72
0.53%
Brent Oil
83.835
-0.60%
Bitcoin
63,731.01
-1.73%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Biogen Inc (0R1B) Quote

Biogen Inc

Biogen Inc (0R1B)

LSE
277.67
0.00
(0.00%)
Closed July 16 11:30AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
277.67
Bid
0.00
Ask
0.00
Volume
0.00
0.00 Day's Range 0.00
277.67 52 Week Range 277.67
Market Cap
40.234B
Previous Close
277.67
Open
-
Last Trade
200
@
221.5
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
4,919
Shares Outstanding
144,898,000
Dividend Yield
-
PE Ratio
27.65
Earnings Per Share (EPS)
8.01
Revenue
9.84B
Net Profit
1.16B

About Biogen Inc

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.biogen.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0R1B. The last closing price for Biogen was $277.67. Over the last year, Biogen shares have traded in a share price range of $ 277.67 to $ 277.67.

Biogen currently has 144,898,000 shares outstanding. The market capitalization of Biogen is $40.23 billion. Biogen has a price to earnings ratio (PE ratio) of 27.65.

0R1B Latest News

More News

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology...

July 02 2024
GlobeNewswire Inc.

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China China is the Third Country to Launch LEQEMBI Following the United States and JapanTOKYO and CAMBRIDGE, Mass...

June 27 2024
GlobeNewswire Inc.

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by Biogen...

June 24 2024
GlobeNewswire Inc.

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease TOKYO and...

June 09 2024
GlobeNewswire Inc.

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic...

May 30 2024
GlobeNewswire Inc.

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Transaction to include felzartamab, a potential first-in-class...

May 22 2024
GlobeNewswire Inc.

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Development of BIIB105, an investigational antisense oligonucleotide for...

May 16 2024
GlobeNewswire Inc.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast...

May 14 2024
GlobeNewswire Inc.

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy New data from the RESPOND...

March 06 2024
UK Regulatory

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting New data advances understanding of new approaches to treating...

March 04 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
100277.67277.67277.6730005277.67DE
400277.67277.67277.6710544277.67DE
1200277.67277.67277.674919277.67DE
2600277.67277.67277.673655277.67DE
5200277.67277.67277.673900277.67DE
15600277.67277.67277.676554277.67DE
26000277.67277.67277.675479277.67DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
SHOTWSafety Shot Inc
$ 0.41
(115.79%)
7.56k
DATSDatChat Inc
$ 1.89
(81.73%)
54.75M
CYNCYNGN Inc
$ 9.18
(53.77%)
17.79M
SCNIScinai Immunotherapeutics Ltd
$ 5.80
(42.86%)
29.37M
ASLNASLAN Pharmaceuticals Ltd
$ 1.36
(-46.67%)
1.16M
KZIAKazia Therapeutics Ltd
$ 0.5593
(-37.56%)
15.34M
LCFYLocafy Ltd
$ 3.5597
(-36.32%)
584.38k
NAASNaaS Technology Inc
$ 2.82
(-33.02%)
1.94M
ZENVZenvia Inc
$ 1.67
(-26.75%)
658.26k
FFIEFaraday Future Intelligent Electric Inc
$ 0.5152
(22.09%)
217.92M
NVDANVIDIA Corporation
$ 128.44
(-0.62%)
208.32M
SQQQProShares UltraPro Short QQQ
$ 7.46
(-0.67%)
155.14M
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
TSLATesla Inc
$ 252.64
(1.78%)
147.31M

Discussion

View Full Feed
GVInvestments GVInvestments 2 minutes ago
I'm holding till $300.00 per share.
FNMA
HippyTrades HippyTrades 2 minutes ago
Your head is literally spinning because you know that was a horrible annual report and you can't face it
AXXA
vinmantoo vinmantoo 5 minutes ago
No data on clinical endpoints.

Thanks for the link. Pretty telling that they didn't include symptom relief data.
HippyTrades HippyTrades 6 minutes ago
The buyback fund?
Wow do you ever make stuff up.
What do you think a disclosure is?
AXXA
DocLee DocLee 7 minutes ago
Another effective treatment (Car-T) for brain tumours (this time in children) which might complement DCVax (and would be less toxic). The article is in Nature at https://www.nature.com/articles/d41586-024-02255-2?utm_source=Live+Audience&utm_campaign=f8586bf0ce-nature-briefing-daily-20240715&utm_me
NWBO
Wise Man Wise Man 12 minutes ago
Error in the hyperlink to the CFR 1229.13 posted before, that inserted a new capital distribution: the Lamberth rebate (Number 3), thanks to an express grant of authority of FHFA in the law to do it (Number 3 in the FHEFSSA definition of capital distribution, posted before).
Chevron deference
FNMA
nowwhat2 nowwhat2 15 minutes ago
1 HR LATER.......


https://investorshub.advfn.com/uimage/uploads/2024/7/16/qtmkceth_777_15_5d_945pm_chan_3500_Gee.jpg

1 HR LATER.......WHUMP !
https://investorshub.advfn.com/uimage/uploads/2024/7/16/facjveth_777_15_5d_1045pm_chan_3500_WHUMP.jpg
BTCUSD
nowwhat2 nowwhat2 16 minutes ago
1 HR LATER.......


https://investorshub.advfn.com/uimage/uploads/2024/7/16/qtmkceth_777_15_5d_945pm_chan_3500_Gee.jpg

1 HR LATER.......WHUMP !
https://investorshub.advfn.com/uimage/uploads/2024/7/16/facjveth_777_15_5d_1045pm_chan_3500_WHUMP.jpg
ETHUSD
Sltan Sltan 18 minutes ago
100X
RNVA
Sltan Sltan 19 minutes ago
I hope we see
0.01
Earnings results
Fusion
to divide
Million profits
Price 0.0001
Chance of achieving x100
🤑🤑🤑🤑🤑🤑
RNVA
sentiment_stocks sentiment_stocks 24 minutes ago
And if your feeling particularly brave, why not contact the Chair of the CHM ?..

p.mulholland@ucl.ac.uk

You know that it was Paul Mullholland who presented the DCVax-L P3 data results at New York Academy of Sciences in about an hour long presentation on May 20, 2023, ri
NWBO
cootcat cootcat 26 minutes ago
60f1 you just show up to let us know this is a scam. ARE you new or just a different name? But you are not the first to make that statement or that claim. One has to remember that this is micro penny stock. How many micro pennies stock are call scams and actual are?
ILUS
rikkie rikkie 29 minutes ago
Calimero !
LWLG
BugStrong BugStrong 32 minutes ago
Today we shall see how the flow is.
WDLF
LazyInvestor LazyInvestor 34 minutes ago
What do you mean? The only financial records they needed to be current were for the 10Q for Q1 which were due in May. Or am I missing something here?
BEGI
BugStrong BugStrong 37 minutes ago
I thought more info on the companies in the incubator would have been talked, more details.
WDLF
Louinjaxxx Louinjaxxx 38 minutes ago
Maybe you don't want the company to audit the lndustries the company is involved in because it could make the company a great find in OTCMarkets.

Maybe you don't like how the CEO is managing the company because you think you could do better (CEO- envy).
AXXA
Wise Man Wise Man 40 minutes ago
Summary of the current state of Fanniegate: Chevron deference🆚Rogues.

Justice Alito can't make laws. What he was doing with his opinion, was to endorse the Separate Account plan, whether he likes it or not. His spin isn't even taken into consideration: "Rehabilitate FnF in a w
FNMA
Twister Twister 40 minutes ago
Military AR perhaps brighter than events/delays have appeared!

Delayed acceptance, budgets and depth of product scope remain attractive.
Corporate belt tightening is very real and military training budget cuts likely to continue.

Seeing continued interest by othe
VTSI
Fdc4 Fdc4 44 minutes ago
I wouldn’t be surprised if it is higher. JFHE posted Q2 coming and strong. So, it shall be higher at least. What I don’t understand is why name change is taking too long
IGPK
Louinjaxxx Louinjaxxx 44 minutes ago
It depends...which do you prefer, 62 mil debt or 31 mil debt?
AXXA
conix conix 45 minutes ago
Things are really looking up for Biden to roll over Trump in November.

Stay Positive. Biden did GREAT in that Lester Holt interview this evening. Sharp as a tack.

spdpro spdpro 47 minutes ago
D > interesting
In the "past" with StreetSmartPro you could do that with advanced brackets >

I'm looking at TOS Web now and do not see any way to do things outside
of 2 differing order trades on 2 trade tickets to accomplish your 1 goal >
Even with >>> And Or
Acme Investments Acme Investments 49 minutes ago
Don't want to put the cart before the horse but I have a few tickers you may be interested in!! AFFY, XREG, ICBT, FRCN, XSPT and last but not least IFLM!! All expert and I own shares in them!!
AFFY FRCN IFLM
US-JUSTICE US-JUSTICE 51 minutes ago
there is no peace in hell for the condemned to burn in hell. eternal damnation!

Your Recent History

LSE
0R1B
Biogen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved